Daily Stock List
Helius Medical Technologies, Inc. (HSDT)
We are highlighting Helius Medical Technologies, Inc. (HSDT) today, here at the QualityStocks Daily Newsletter.
Helius Medical Technologies, Inc. is a medical technology company based in Newtown, Pennsylvania. The Company’s emphasis is neurological wellness. Helius works to develop, license, and acquire inventive non-invasive treatments designed to amplify the brain’s ability to heal itself. NeuroHabilitation is a division of Helius Medical Technologies. NeuroHabilitation is developing an innovative technology as a potential treatment for neurological symptoms caused by disease or trauma.
Helius Medical Technologies’ intention is to file for U.S. Food and Drug Administration (FDA) clearance for the PoNS™ device. The PoNS™ device is a non-invasive means for delivering neurostimulation by way of the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. PoNS™ Therapy combines the use of the device with physical therapy. Right now, it is undergoing evaluation in a multicenter clinical trial for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).
In 2013, the NeuroHabilitation division signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense. This is to develop and manage clinical and regulatory activities for the PoNS™ device and CN-NINM technologies.
Helius announced in July of 2015 that NeuroHabilitation successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract will support Helius’ registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS™). The PoNS™ is being studied in Canada for chronic balance and gait symptoms caused by Multiple Sclerosis.
This month, Helius Medical Technologies and HealthTech Connex, Inc. (HTC) announced, based on favorable preliminary results, the expansion of a wide-ranging study to further characterize physiological changes in improved cognitive function resulting from investigational PoNS™ Therapy in healthy subjects. Characterizing the brain’s healing response to neurological trauma or disease is an important research goal for Helius and HTC. This shared emphasis resulted in HTC partnering as a clinical site for Helius’ registrational study in balance disorder resulting from Traumatic Brain Injury (TBI).
Today, Helius Medical Technologies, along with the Tactile Communication and Neurorehabilitation Laboratory (TCNL) of the University of Wisconsin-Madison, announced that the last subject was randomized in a 44-subject clinical trial investigating PoNS™ Therapy for the treatment of chronic balance deficits because of traumatic brain injury (TBI). The trial is now completely enrolled.
Helius Medical Technologies, Inc. (HSDT), closed Monday's trading session at $1.70, up 13.33%, on 10,170 volume with 11 trades. The average volume for the last 60 days is 4,353 and the stock's 52-week low/high is $0.68/$1.58.
MassRoots, Inc. (MSRT)
OTCtipReporter, PennyStockScholar, Profitable Trader Authority, SmallCapVoice, SeeThruEquity Research, Penny Picks, Damn Good Penny Picks, Stock News Now, Stock Commander, CFN Media Group, Energy and Capital, MarketWatch, StreetInsider, Stock Gumshoe, Promotion Stock Secrets, Top Pros' Top Picks, Wealth Daily, Cannabis Financial Network News, and Equities reported on MassRoots, Inc. (MSRT), and today we report on the Company, here at the QualityStocks Daily Newsletter.
MassRoots, Inc. is one of the largest and fastest growing technology platforms for the cannabis industry. Individuals use the Company’s application to share their cannabis experiences, and stay connected with local dispensaries. The Company has over 900,000 users - as of late May 2016 - of its technology platforms. MassRoots has affiliations with the top organizations in the cannabis industry. These include the ArcView Group and the National Cannabis Industry Association. MassRoots is based in Denver, Colorado.
The Company’s plan is on expanding to multiple states. Businesses can use the Company to advertise their goods and services to cannabis consumers. MassRoots starts adding in features, including order ahead, delivery, and the in-app purchase of ancillary products as regulations permit. Cannabis enthusiasts collectively engage more than 300,000 times per day on MassRoots’ network.
MassRoots has an estimated 300-plus dispensaries actively posting on its network. These include the nation's leading dispensaries: Native Roots, MiNDFUL, The Clinic, BuddyBoyBrands, Green Solution, Good Chemistry, Denver Relief, Natural Remedies, and Harborside Health Center. The Company’s product pipeline includes Dispensary Finder & Menus; Product Pages & Reviews; Sponsored Posts 2.0; and Enhanced Profiles. Most of its advertising revenue has come from dispensaries and cannabis-brands in California and Colorado.
Additionally, the Company is partnering and taking an equity position in a full seed-to-sale system. This system is now operating in stealth under the name Flowhub during private beta. The MassRoots and Flowhub development teams are integrating their systems, expanding the services available to MassRoots' users and dispensaries.
Today, MassRoots and MJ Freeway announced that MJ Freeway's API will power live menu pricing for its dispensary clients within the MassRoots platform. MJ Freeway is the foremost point-of-sale (POS) and compliance management platform centered on the cannabis industry.
MassRoots’ Chief Executive Officer, Mr. Isaac Dietrich, said, "MJ Freeway is the undisputed leader in seed-to-sale tracking software and powers nearly half of all transactions in the regulated cannabis industry. This partnership will enable seamless communications between MJ Freeway's thousands of dispensary clients and MassRoots' community of hundreds of thousands of cannabis consumers.”
MassRoots, Inc. (MSRT), closed Monday's trading session at $0.77, up 5.48%, on 1,572,833 volume with 1,116 trades. The average volume for the last 60 days is 1,413,172 and the stock's 52-week low/high is $0.38/$1.67.
CytoDyn, Inc. (CYDY)
SeeThruEquity Research, Stock News Now, PennyStockScholar, Profitable Trader Authority, OTCtipReporter, StockOodles, PennyStockRumors.net, and AllPennyStocks reported on CytoDyn, Inc. (CYDY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
CytoDyn, Inc. is a biotechnology company headquartered in Vancouver, Washington. The Company is focusing on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). CytoDyn has one of the leading mAbs under development for HIV infection: PRO 140. This mAb is the Company’s novel self-injectable antibody for the treatment of HIV. PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is now in Phase 3.
PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells. PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors. The intention of these are to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results to date indicate that it does not affect the normal function of the cell.
Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can considerably diminish viral burden in people infected with HIV. A Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. The Company’s objective is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. PRO 140 has also been designated a "fast track" product candidate by the Food and Drug Administration (FDA).
CytoDyn’s completed Phase 2b treatment substitution trial demonstrated that 98 percent of all patients treated with PRO 140 successfully passed four weeks of monotherapy without virologic failure. CytoDyn said that its research data has expanded the potential clinical indications for PRO 140 to include certain inflammatory diseases, autoimmunity, transplantation, and cancer.
Recently, CytoDyn announced that it filed a new roll-over protocol permitting all ongoing patients who reach the end of the Phase 3 combination study to continue receiving PRO 140. The main intention of this roll-over protocol is to provide PRO 140 for a second patient, who completed the study, and all other future patients who complete participation in the Phase 3 combination study and would require continual access to PRO 140 to form a viable regimen, in the judgment of the treating physician.
In November, CytoDyn announced that an abstract featuring results from its continuing Phase 2b extension study with PRO 140 as a monotherapy for the treatment of patients with HIV was accepted for a poster presentation, and also a “themed discussion” at the Conference on Retroviruses and Opportunistic Infections (CROI), which will take place in Seattle, Washington from February 13 to 16, 2017.
CytoDyn, Inc. (CYDY), closed Monday's trading session at $0.795, up 9.05%, on 1,712,526 volume with 522 trades. The average volume for the last 60 days is 325,415 and the stock's 52-week low/high is $0.61/$1.57.
CV Sciences, Inc. (CVSI)
Today we are highlighting CV Sciences, Inc. (CVSI), here at the QualityStocks Daily Newsletter.
CV Sciences, Inc. centers on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). A life science company, it operates two divisions - Consumer Products and Pharmaceuticals. These divisions are supported by its medical and scientific advisory board, and state‐of‐the art production facilities. The Company previously went by the name CannaVEST Corp. It changed its name to CV Sciences, Inc. in January of this year. CV Sciences has main offices and facilities in Las Vegas, Nevada, and San Diego, California.
Its Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Each consumer products brand is backed by a formal safety review, an increasing body of case reports, and physician’s recommendations. The CBD Consumer Division has grown from 120 retail locations to more than 700 locations.
The Company’s Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine. It is pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. CV Sciences has attained promising preclinical results in the development of cannabinoid medicines for the treatment of an array of medical conditions.
Moreover, CV Sciences manufactures, markets, and sells plant-based CBD products under the PlusCBD brand. This is for a variety of market sectors, including nutraceutical, beauty care, specialty foods, and vape.
CV Sciences acquired CanX, Inc. in December 2015. CanX is a Pre-Clinical drug development company. It is concentrating on significant unmet medical needs. CanX’s initial drug candidate is CVSI-007. CVSI-007 chewing gum combines CBD and Nicotine and it is patent pending. CVSI-007 is a proprietary chewing gum, which combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.
CV Sciences began its preclinical drug development program during Q2 2016, following the CanX acquisition. Its drug development efforts include pursuing synthetic-based Cannabidiol (CBD) drug candidates in areas that have the potential to provide key improvements in therapeutic patient treatments with substantial addressable markets.
The latest addition to the Company’s consumer products division is Purified Liquids™ (high quality, premium CBD vape e-liquids). The launch of this brand targets the growing vape industry. Purified Liquids™ is made from 99.9 percent CBD from hemp-derived crystals and contains 0 percent THC. Each Purified Liquids™ product provides a minimum of 360mg of hemp-derived CBD per 30mL bottle, offering 12mg of CBD per mL.
Regarding CV Sciences’ natural products sales, they were $2.94 million for Q3 2016. This includes distribution to greater than 775 stores. The Company said that expanded education and marketing efforts propelled these sales.
CV Sciences, Inc. (CVSI), closed Monday's trading session at $0.275, up 0.41%, on 644,251 volume with 211 trades. The average volume for the last 60 days is 1,319,294 and the stock's 52-week low/high is $0.10/$0.9866.
ABCO Energy, Inc. (ABCE)
POSstocks, Penny Stocks On Steroids, and PennyStock Tweets reported on ABCO Energy, Inc. (ABCE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
ABCO Energy, Inc. is an Arizona licensed contractor for the sales and installation of Photovoltaic Solar Systems, Solar Street Lighting, and the installation of LED and energy conservation lighting systems in its markets. The Company provides products and services for residential, commercial, government and non-profit entities in all its markets. Established in 2008, ABCO Energy has its headquarters in Tucson, Arizona.
ABCO Solar is a partner with ABCO Energy. ABCO Solar is a full-service, licensed electrical contractor. It assists its customers with every stage of their solar panel installation. This includes size determination, financing options, tax and utility incentives.
ABCO Energy sells and installs solar photovoltaic electric systems that enable customers to produce power on their residence or business property. ABCO Energy also sells and installs energy efficient lighting products, solar powered street lights, and lighting accessories to residential and commercial customers. Furthermore, it provides solar leasing and long term financing programs to its customers and other marketing and installation organizations.
In December 2015, ABCO Energy announced the completion of a 70,560 Watt DC voltage first phase, and another smaller project of 22,500 Watt DC of its backlogged commercial solar projects. The system will provide shaded parking for up to 48 recreational vehicles.
All steel components were built by Park N Shade steel contractors of Tucson, Arizona. ABCO Energy completed all solar system components, system design, permitting, and electrical interconnection to set the system online in December 2015.
This past April, ABCO Energy announced the construction launch of a 68.04 Kilowatt project in the Phoenix Metropolitan area. The project is part of a chain of five projects consisting of parking structures with solar on the roofs and the parking of Recreational Vehicles (RVs) underneath. This is the third of five such projects contracted in 2015 with the remaining three construction completion dates this year. This project will provide electricity for the whole storage center.
Pertaining to Photovoltaic Residential Solar Systems, an ABCO Energy Solar System includes personalized system design; equipment and connectivity; drawings and permitting with all local jurisdictions. It also includes professional installation; system testing; and any required local government and utility company inspections.
ABCO Energy, Inc. (ABCE), closed Monday's trading session at $0.0044, up 12.82%, on 15,350,499 volume with 140 trades. The average volume for the last 60 days is 15,071,041 and the stock's 52-week low/high is $0.003/$0.23.
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0016, up 14.29%, on 4,331,502 volume with 30 trades. The stock’s average daily volume over the past 60 days is 18,087,491 and its 52-week low/high is $0.001/$0.058.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Dominovas Energy Dispatches Watkins to Meet With Gas Supplier
GainClients, Inc. (GCLT)
The QualityStocks Daily Newsletter would like to spotlight GainClients, Inc. (GCLT). Today, GainClients, Inc. closed trading at $0.05, up 7.99%, on 107,018 volume with 12 trades. The stock’s average daily volume over the past 60 days is 180,615, and its 52-week low/high is $0.01/$0.20.
GainClients, Inc. (GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company's innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data.
The company's main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions.
Similar to the features of other popular online networks, professional users can invite clients and their industry partners to join their GCard networks and be featured as trusted team members. From here, the teams can quickly provide real estate, lending and title services and information to consumers via smartphone and web. With better communication throughout the process of buying or selling homes, purchases can move more quickly and more comfortably to completion.
Strategic partnerships are an important component of GainClients' growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies' proprietary technologies to the real estate industry. CLOVIS will use GainClients' GCard to develop a unique lead generation program for the broader real estate marketing and advertising industry.
GainClients also offers GCHomeSearch, its stand-alone website that provides non-real estate customers, such as lenders and title professionals, with accurate listing data, historical property data, neighborhood information and demographics. When used with the GCard, the user is also privy to loan payment calculators, loan rates, closing cost estimators and other tools needed to make intelligent buying and selling choices. Disclaimer
GainClients, Inc. Company Blog
GainClients, Inc. News:
GainClients, Inc. Retains Largest Real Estate Customer on its GCard Service
GainClients, Inc. Announces Corporate Update
GainClients, Inc. Enters Into A Licensing Agreement with Real Estate Technology Upstart CLOVIS, LLC To Expand Its Technology Platform
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $4.25, up 1.19%, on 2,257 volume with 13 trades. The stock’s average daily volume over the past 60 days is 31,613, and its 52-week low/high is $0.6101/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
Marsee Wilhems Team Joins eXp Realty in Tucson
Fundamental Research Corp. Updates its Coverage of eXp World Holdings, Inc.
eXp World Holdings, Inc. Reports Record Revenue and Growth for Third Quarter 2016
OurPet's Company (OPCO)
The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $1.02, up 1.02%, on 9,750 volume with 7 trades. The stock’s average daily volume over the past 60 days is 4,795, and its 52-week low/high is $0.6882/$1.06.
OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.
In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.
The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.
OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer
OurPet's Company Company Blog
OurPet's Company News:
OurPet's Company to Webcast, Live, at VirtualInvestorConferences December 1
OurPetís Company Reports Record Third Quarter 2016 Results
OurPet's Company CFO to Present at the MicroCap Conference in Philadelphia
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.50, off by 10.71%, on 20,913 volume with 22 trades. The stock’s average daily volume over the past 60 days is 10,136, and its 52-week low/high is $1.10/$5.00.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Recruiter.com Launches Custom Travel & Loyalty Program via Monaker Group Partnership
Monaker Groups Alternative Lodging Vacation Rentals Gain Exposure to Decision Makers at Over One Million Companies Worldwide
Monaker Group Achieves Key Milestone - Application Program Interface (API) and Booking Engine Complete
Today's Top 3
Profitable Trader Authority
The QualityStocks Public Company Sponsor News